Results 31 to 40 of about 10,308 (152)
Small Structures, Volume 7, Issue 7, July 2026.Surface engineering converts pollen‐derived sporopollenin capsules into functional tools for medicine. Chemical, biological, and physical modifications give these natural carriers new properties. The modified capsules can release drugs on demand, recognize diseased tissues, and assist in diagnosis.
Qian Liu +9 more
wiley +1 more source
OncoImmunology, 2018 Several studies support the notion that the kinase inhibitor Imatinib mesylate exerts off-target effects on cells of the immune system. After our first report of continuous daily oral administration in subjects with relapsed/refractory neuroblastoma (NB,
Fabio Morandi +12 more
doaj +1 more source
Kinetic Fingerprints as Mechanistic and Clinical Roadmaps Across KIT Activation States
ChemMedChem, Volume 21, Issue 11, 15 June 2026.Kinetic profiling of 172 compounds across KIT conformations—including D816V—reveals kinetic fingerprints that predict efficacy, selectivity, resistance, and inhibitors’ ability to stabilize key regulatory elements. Far from a secondary metric, binding kinetics provide mechanistic insights beyond affinity, offering a powerful framework for rational drug
Ana Corrionero +7 more
wiley +1 more source
Veterinární Medicína, 2020 A two-year-old spayed female American shorthair cat presented with a rough, circular, exophytic mass on the genital area. The clinical findings and histopathological examination revealed that the mass contained neoplastic mast cells and, thus, was ...
Joonyoung Kim, Ha-Jung Kim
doaj +1 more source
Formulation and in vitro, in vivo evaluation of effervescent floating sustained-release imatinib mesylate tablet. [PDF]
PLoS ONE, 2015 Imatinib mesylate is an antineoplastic agent which has high absorption in the upper part of the gastrointestinal tract (GIT). Conventional imatinib mesylate (Gleevec) tablets produce rapid and relatively high peak blood levels and requires frequent ...
Ali Kadivar +7 more
doaj +1 more source
Outcome of imatinib mesylate in women with child-bearing age diagnosed with chronic myeloid leukemia
Iraqi Journal of Hematology, 2021 BACKGROUND: Imatinib Mesylate (IM) is an oral tyrosine kinase inhibitor, which demonstrates great effect in the treatment of both chronic myeloid leukemia (CML) and gastrointestinal stromal tumors.
Alaa Fadhil Alwan +3 more
doaj +1 more source
Effect of astaxanthin in imatinib mesylate-induced cardiotoxicity
Acta Medica Alanya, 2020 Aim: Imatinib mesylate is a tyrosine kinase inhibitor and is approved as a standard first-line therapy of chronic myeloid leukemia. Oxidative stress, as well as intracellular calcium overload and mitochondrial dysfunction, play an important role in ...
İshak Suat Övey, Can Ramazan Öncel
doaj
iNew Medicine, Volume 2, Issue 2, June 2026.ABSTRACT High‐grade serous ovarian cancer (HGSOC) is the most common and lethal histological subtype of ovarian cancer. This study aimed to identify peritoneal metastasis‐associated biomarkers of HGSOC to provide directions for subsequent treatment. Transcriptome data were extracted from the GEO database and literature. Differential expression analysis,
Jing Zhu +8 more
wiley +1 more source
The Dual Role of Autophagy in Cancer: Mechanisms and Therapeutic Strategies
MedComm – Oncology, Volume 5, Issue 2, June 2026.Autophagy is a conserved cellular process degrading dysfunctional organelles and protein aggregates to maintain cell homeostasis, and it exhibits context‐dependent duality in cancer. Autophagy functions as a critical tumor‐suppressive mechanism by preventing DNA damage and mutation during tumor initiation.
Xiang‐Zheng Gao +4 more
wiley +1 more source
Beta Thalassemia and Chronic Myeloid Leukemia: Dual Diagnosis Under the Microscope
International Journal of Laboratory Hematology, Volume 48, Issue 5, Page 931-933, October 2026.
Paige Muir +3 more
wiley +1 more source